PANCRELIPASE (X-GEN Pharmaceuticals, Inc.)


Welcome to the PulseAid listing for the PANCRELIPASE drug offered from X-GEN Pharmaceuticals, Inc.. This pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: X-GEN Pharmaceuticals, Inc.
NON-PROPRIETARY NAME: pancrelipase
SUBSTANCE NAME: PANCRELIPASE LIPASE; PANCRELIPASE PROTEASE; PANCRELIPASE AMYLASE
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS:
ROUTE: ORAL
DOSAGE FORM: CAPSULE, DELAYED RELEASE
MARKETING CATEGORY NAME: NDA AUTHORIZED GENERIC
START MARKETING DATE: 2009-09-22
END MARKETING DATE: 2018-03-31


PANCRELIPASE HUMAN PRESCRIPTION DRUG Details:

Item DescriptionPANCRELIPASE from X-GEN Pharmaceuticals, Inc.
LABELER NAME: X-GEN Pharmaceuticals, Inc.
DEA SCHEDULE:
ACTIVE STRENGTH: 5000; 17000; 27000([USP’U]/1; [USP’U]/1; [USP’U]/1)
START MARKETING DATE: 2009-09-22
END MARKETING DATE: 2018-03-31
PRODUCT ID: 39822-0205_43e9cfd8-26e6-4d38-a41e-de39b9329b8a
PRODUCT NDC: 39822-0205
APPLICATION NUMBER: NDA022210

Other PANCRELIPASE LIPASE; PANCRELIPASE PROTEASE; PANCRELIPASE AMYLASE Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
AbbVie Inc.Creon
Allergan, Inc.Zenpep
Aptalis Pharma US, IncULTRESA
Aptalis Pharma US, Inc.ZENPEP
Atlantic Biologicals CorpsCreon
Physicians Total Care, Inc.ZENPEP
X-GEN Pharmaceuticals, Inc.PANCRELIPASE